# Efficacy and Safety of Arotinolol Hydrochloride on Morning Blood Pressure and Heart Rate

Study · id `cardio:ct-nct02612298` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02612298](<https://clinicaltrials.gov/study/NCT02612298>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02612298

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 198 participants.

## Technical summary

Registry record NCT02612298. Randomized; no masking; primary purpose treatment. Start 2015-08 (actual); primary completion 2018-09-13 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 198 participants (enrolled count; ClinicalTrials.gov record NCT02612298, source copy `cardio:ctgov-nct02612298-2019-04-17`, retrieved 2026-10-26)
- Started: 2015-08 (actual) (ClinicalTrials.gov record NCT02612298, source copy `cardio:ctgov-nct02612298-2019-04-17`, retrieved 2026-10-26)
- Primary completion: 2018-09-13 (actual) (ClinicalTrials.gov record NCT02612298, source copy `cardio:ctgov-nct02612298-2019-04-17`, retrieved 2026-10-26)
- Completion: 2018-09-13 (actual) (ClinicalTrials.gov record NCT02612298, source copy `cardio:ctgov-nct02612298-2019-04-17`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT02612298, source copy `cardio:ctgov-nct02612298-2019-04-17`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02612298-2019-04-17`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of Arotinolol Hydrochloride on Morning Blood Pressure and Heart Rate
- Acronym: ESAHOM
- Condition: Essential Hypertension
- Intervention (Drug): Arotinolol Hydrochloride
- Intervention (Drug): Metoprolol succinate sustained-release tablet
- Lead sponsor: Marubeni Pharmaceuticals (Suzhou) Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Marubeni Pharmaceuticals (Suzhou) Co., Ltd. (`cardio:org-marubeni-pharmaceuticals-suzhou-co-ltd`)

## Provenance

Content hash: e8c9d5a5dd9969016dcc100ebaea78ef217ac674f319ee65c2395ef15b9dec8d
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
